August 4, 2025
Our Work
Latham & Watkins Advises HilleVax in Acquisition by XOMA Royalty for US$1.95 in Cash Per Share Plus a Contingent Value Right via a Tender Offer
Multidisciplinary deal team represents the clinical-stage biopharmaceutical company in the transaction.